Tesamorelin 5 mg

Tesamorelin 5 mg is a research peptide supplied as a lyophilized powder. In medical practice, tesamorelin is FDA-approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. In bodybuilding research contexts, it is referenced for its effects on the GH/IGF-1 axis and body composition, though such use falls outside approved indications.

In clinical trials, tesamorelin was administered as 2 mg subcutaneously once daily. Non-medical bodybuilding protocols often reference daily administration, sometimes with a 5-days-on, 2-days-off schedule. Administration frequency should align with the specific research protocol and individual factors.

Tesamorelin is not an anabolic steroid and does not suppress endogenous testosterone production in the same way. Post-cycle therapy designed for steroid cycles is not typically referenced in the context of tesamorelin research. However, the GH/IGF-1 axis does have its own feedback mechanisms that researchers may consider.

Tesamorelin is a GHRH analogue that binds to growth hormone-releasing hormone receptors on the pituitary gland, stimulating the synthesis and pulsatile release of endogenous growth hormone. This leads to downstream increases in IGF-1 and effects on metabolism and body composition. It is distinct from exogenous HGH because it works through the body's own pituitary signalling.

Clinical studies measured effects on visceral adipose tissue over 26 to 52 weeks of treatment. Growth hormone and IGF-1 levels increase relatively quickly after administration, but changes in body composition develop over longer periods. Individual response timelines vary based on multiple factors.

Tesamorelin is the only GHRH analogue with FDA approval for a specific indication—HIV-associated lipodystrophy. Other GHRH analogues such as Sermorelin have different pharmacokinetic profiles and approval histories. The "best" choice depends on the specific research or clinical context.

Both tesamorelin and sermorelin are GHRH analogues, but they differ in their amino acid sequences and pharmacokinetic profiles. Tesamorelin contains the full 44-amino-acid sequence of human GHRH, while sermorelin is a shorter fragment. Tesamorelin has been more extensively studied in clinical trials for visceral fat reduction.

Tesamorelin and Ipamorelin work through different mechanisms. Tesamorelin activates GHRH receptors, while ipamorelin is a ghrelin receptor agonist that stimulates GH release through a separate pathway. A combined Ipamorelin and Tesamorelin product is available for researchers examining both pathways.

2 mg once daily is the dose used in the clinical trials that supported tesamorelin's FDA approval. In non-medical contexts, some users reference lower doses for cost management or side effect considerations. As with any peptide, individual response and tolerance vary.

Tesamorelin 5 mg by Dragon Pharma contains 5 mg of tesamorelin per vial as a lyophilized powder. The vial size is 2 mL. This is a research-strength presentation that allows for flexible dosing depending on the reconstitution volume used.

No laboratory report is currently published for this specific Tesamorelin 5 mg product listing. Dragon Pharma products are generally subject to quality control, but no third-party laboratory report is available for this batch at this time. Researchers should verify product authenticity through the manufacturer's security features.

Tesamorelin is sometimes referenced alongside other GH-related peptides in research contexts. CJC-1295 No DAC / Ipamorelin represents another approach to GH axis stimulation. The combined Ipamorelin and Tesamorelin product exists specifically for researchers examining complementary mechanisms.